Research &
Publications
Over the past 30 years, Dr. Odze’s research has focused mainly on the development and progression of cancer in chronic inflammatory conditions of the GI tract, such as Barrett's Esophagus and Inflammatory Bowel Disease: In particular, mechanisms of metaplasia, pathologic and molecular pathways of the inflammation-dysplasia-carcinoma sequence, as well as various other molecular, diagnostic and prognostic issues related to these disorders. The pathologic and biological characteristics, and natural history, of neoplastic precursor lesions, such as dysplasia, as well as predictive factors of recurrence and survival in patients with these conditions, has been his areas of active investigation for more than 15 years. A small sample of Dr. Odze’s research publications are listed below. A complete list of publications can be accessed using the link below.
Noteworthy Publications in Barrett’s Esophagus
1. Pathology of Barrett's. My work focused on the phenotypic characteristics of early changes in Barrett's Esophagus, mechanisms by which Barrett's Esophagus develops, and mechanisms to differentiate esophageal from gastric mucosa.
Glickman JN, Chen YY, Wang H, Antonioli DA, Odze RD. Phenotypic characteristics of a distinctive multilayered epithelium suggests that it is a precursor in the development of Barrett's Esophagus. Am J Surg Pathol 2001;25(5):569-578. (PMID: 11342767)
Shields H, Rosenberg SJ, Zwas FR, Ransil B, Lembo AJ, Odze RD. Prospective evaluation of multilayered epithelium in Barrett's Esophagus. Am J Gastroenterol 2001;96(12):3268-3273. (PMID: 11774935)
Srivastava A, Odze RD, Lauwers G, Redston M, Antonioli D, Glickman JN. Morphologic features are useful in distinguishing Barrett's Esophagus from carditis with intestinal metaplasia. Am J Surg Pathol 2007 Nov;31(11):1733-1741. (PMID: 18059231)
Hahn H, Blount PL, Ayub K, Das K, Souza R, Spechler S, Odze RD. Intestinal differentiation in metaplastic non-goblet columnar epithelium in the esophagus. Am J Surg Pathol 2009;33(7):1006-15. (PMID: 19363439)
2. Pathology, molecular biology and natural history of dysplasia precursor lesions in Barrett's Esophagus.
Dorer R, Odze RD. AMACR Immunostaining is useful in detecting dysplastic epithelium in Barrett’s esophagus, ulcerative colitis and Crohn’s disease. Am J Surg Pathol 2006 Jul;30(7):871-877. (PMID: 16819330)
Lomo L, Blount PL, Sanchez CA, Cowan DS, Ayub K, Reid BJ, Odze RD. Crypt dysplasia with surface matureation: a clinical, pathologic and molecular study of Barrett's Esophagus cohort. Am J Surg Pathol 2006;30(4):423-435. (PMID:16625087)
Srivastava A, Hornick JL, Blount PL, Li X, Sanchez CA, Cowan DS, Ayub K, Maley CC, Reid BJ, Odze RD. Extent of low-grade dysplasia is a risk factor for the development of esophageal adenocarcinoma in Barrett's Esophagus. Am J Gastroenterol 2007;102(3):483-493. (PMID: 17338734)
Zhang X, Huang Q, Goyal R, Odze RD. DNA ploidy abnormalities in basal and superficial regions of the crypts in Barrett's Esophagus and associated neoplastic lesions. Am J Surg Pathol 2008;32(9):1327-1335. (PMID: 18670357)
Rucker-Schmidt R, Sanchez C, Blount P, Ayub K, Li X, Rabinovitch P, Reid B, Odze RD. Non-adenomatous dysplasia in Barrett's Esophagus; a clinical, pathologic and DNA content flow cytometric study. Am J Surg Pathol 2009 Jun;33(6):886-93. (PMID: 19194279)
3. Molecular mechanisms in which Barrett's Esophagus develops dysplasia, and how it progresses to carcinoma and risk factors associated with neoplastic progression.
Lai LA, Kostadinov R, Barrett MT, Peiffer DA, Pokholok D, Odze RD, Sanchez CA, Maley C, Reid BJ, Gunderson KL, Rabinovitch P. Deletion at fragile sites is a common and early event in Barrett's Esophagus. Mol Cancer Res 2010 Aug;8(8):1084-94. (PMID: 20647332)
Paulson T, Maley C, Li X, Li H, Sanchez C, Chao D, Odze RD, Vaughan T, Blount P, Reid B. Chromosomal instability and copy number alterations in Barrett's Esophagus and esophageal adenocarcinoma. Clin Cancer Res 2009 May 15;15(10):3305-3314. (PMID: 19417022)
Paulson TG, Galipeau PC, Xu L, Kissel H, Li X, Blount P, Sanchez C, Odze RD, Reid BJ. p16 mutation spectrum in the premalignant condition Barrett's Esophagus. PloS ONE 2008 3(11):e3809.doi:10.1371/journal.pone.0003809 (PMID: 19043591)
Kostadinov RL, Kuhner MK, Sanchez CA, Galipeau PC, Paulson TG, Li X, Sather CL, Srivastava A, Odze RD, Blount PL, Vaughan TL, Reid BJ, Maley CC. NSAIDs modulate clonal evaluation in Barrett's Esophagus. PLoS Genet 2013 Jun;9(6):e1003553. (PMID: 23785299)
Li X, Galipeau PC, Paulson TG, Sanchez CA, Arnaudo J, Liu K, Cowan DS, Sather CL, Kostadinov RL, Maley CC, Odze RD, Blount PL, Self SG, Vaughan TL, Reid BJ. Temporal and spatial evolution of somatic chromosomal alteration: A case-cohort study of Barrett's Esophagus. Cancer Prev Res 2014 Jan;7(1):114-27. (PMID: 24253313)
4. Prognostic factors in patients who have Barrett's Esophagus-associated adenocarcinomas.
Torres C, Turner J, Want H, Richards W, Sugarbaker D, Shahsafaei A, Odze R. Prognostic factors in Barrett’s-associated adenocarcinoma: A clinicopathologic and follow-up study of 96 patients. Cancer 1999;85:520-528.(PMID: 10091725)
Glickman J, Torres C, Wang H, Turner J, Shahsafaei A, Richards W, Odze RD. Lymph node micrometastasis in esophageal carcinoma has no prognostic significance. Cancer 1999;85:769-778. (PMID: 10091753)
Agoston AT, Zheng Y, Bueno R, Lauwers GY, Odze RD, Srivastava A. Clinicopathologic Predictors of Long Term and Disease-Free Survival in Esophageal Adenocarcinomas with Complete Pathologic Response to Neoadjuvant Chemoradiation. United States & Canadian Academy of Pathology, 2013 Annual Meeting Platform Presentation, Baltimore, MD. (Manuscript in Preparation)
Agoston AT, Dulai PS, Rothstein RI, Odze RD, Srivastava A. Predictors of Durable Treatment Response after Radiofrequency Ablation for Barrett’s Esophagus Associated Intramucosal Adenocarcinoma. Platform Presentation, United States & Canadian Academy of Pathology, 2014 Annual Meeting, San Diego, CA. (Manuscript in Preparation)
Noteworthy Publications in Inflammatory Bowel Disease
Hamilton MJ, Makrauer FM, Golden K, Wang H, Friedman S, Burakoff R, Levine JS, Joshi P, Banks PA, Odze RD. Prospective evaluation of terminal ileitis in a surveillance population of ulcerative colitis patients. Inflamm Bowel Dis 2016 Oct;22(10):2448-55.
Shen J, Gibson JA, Schulte S, Khurana H, Farraye F, Levine J, Burakoff R, Cerda S, Qazi T, Srivastava A, Odze RD. Clinical, pathologic and outcome study of serrated polyps in inflammatory bowel disease. Hum Pathol 2015 Oct;46(10):1548-56.
Star KV, Ho VT, Wang HH, Odze RD. Histologic features in colon biopsies can discriminate mycophenolate from GVHD-induced colitis. Am J Surg Pathol 2013 Sep;37(9):1319-28.
Quinn AM, Farraye FA, Naini BV, Cerda S, Coukos J, Li Y, Khor T, Odze RD. Polypectomy is adequate treatment for adenoma-like dysplastic lesions (DALMs) in Crohn’s disease. Inflamm Bowel Dis 2013;19(6):1186-93.
Hamilton MJ, Rege TA, Odze RD. Adenocarcinoma complicating ulcerative colitis presenting as multiple pseudopolyp-like lesions. Clin Gastro Hepatol 2012;10(6):XXV.
Soucy G, Wang H, Farraye F, Schmidt J, Farris A, Lauwers G, Cerda S, Dendrinos K, Odze RD. Clinical and pathologic analysis of colonic Crohn's disease; including a subgroup with ulcerative colitis-like features. Mod Pathol 2012 Feb;25(2):295-307.
Burakoff R, Chao S, Perencevich M, Ying J, Friedman S, Makrauer F, Odze RD, Khurana H, Liew C. Blood-based biomarkers can differentiated ulcerative colitis from Crohn’s disease and non-IBD diarrhea. Inflamm Bowel Dis 2011 Aug;17(8):1719-25.
Haskell H, Andrews CW, Reddy S, Dendrios K, Farraye F, Stucchi A, Becker JM, Odze RD. Pathologic features and clinical significance of “Backwash” ileitis in ulcerative colitis. Am J Surg Pathol 2005;29(11):1472-1481.
Odze RD, Farraye F, Hecht JL, Hornick J. Long-term follow-up after polypectomy treatment for adenoma-like dysplastic lesions in ulcerative colitis. Clin Gastroenterol Hepatol 2004;2(7):534-541 with Editorial.
For a Complete List of Published Works, please use the following link:
